Windlas Biotech Limited has informed the Exchange regarding a press release dated May 21, 2026, titled " Windlas Biotech Limited Reports its Q4 and FY26 Financial Results ".
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Windlas Biotech reported its 13th consecutive quarter of record revenue with Q4FY26 revenue at Rs 238 Crores (up 18% YoY) and full-year FY26 revenue at Rs 904 Crores (up 19% YoY). The company posted strong profitability with FY26 adjusted EBITDA of Rs 121 Crores (26% growth) and adjusted PAT of Rs 83 Crores (31% growth). Margins expanded — adjusted EBITDA margin at 13.4% and adjusted PAT margin at 9.2%. CDMO vertical led growth at Rs 664 Crores (20% YoY), contributing 73% of consolidated revenue. The company is net debt free with Rs 251 Crores net liquidity and generated Rs 105 Crores cash from operations. EPS grew to Rs 31.60. A Rs 47 Crore buyback was completed and a dividend of Rs 13 Crores (Rs 6.30 per share) is proposed. Plant-6 has achieved mechanical completion and is on track for commercialization in H1 FY27.
Windlas Biotech delivered strong double-digit growth in revenue and profit with margin expansion, a clean balance sheet, and robust cash generation — signalling operational strength and capital efficiency that should support the stock positively.